Laquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptor.

ABSTRACT: Laquinimod is an oral drug currently being evaluated for the treatment of relapsing, remitting, and primary progressive multiple sclerosis and Huntington's disease. Laquinimod exerts beneficial activities on both the peripheral immune system and the CNS with distinctive changes in CNS resident cell populations, especially astrocytes and microglia. Analysis of genome-wide expression data revealed activation of the aryl hydrocarbon receptor (AhR) pathway in laquinimod-treated mice. The AhR pathway modulates the differentiation and function of several cell populations, many of which play an important role in neuroinflammation. We therefore tested the consequences of AhR activation in myelin oligodendrocyte glycoprotein (MOG)-induced experimental autoimmune encephalomyelitis (EAE) using AhR kn

SUBMITTER: Kaye J 

PROVIDER: S-EPMC5068259 | biostudies-literature | 2016 Oct

REPOSITORIES: biostudies-literature